By Sam Boughedda
Investing.com — Shares of Adicet Bio Inc (NASDAQ:ACET) jumped in early Monday trading after it reported positive interim data from its dose escalation int its phase 1 study of a drug for the potential treatment of B-cell Non-Hodgkin’s Lymphoma.
Adicet shares hit a high of $13.80 at the open and currently trade around $12.88, up 31%.
The company explained that as of November 22, the data cutoff, six patients had been enrolled in the trial for the drug called ADI-001. The first two patients enrolled did not reach the assessment, while three of the four evaluable patients achieved responses, including two complete responses and one partial response that investigators described as a near-complete response.
"Data to-date suggest that ADI-001 is highly clinically active. We look forward to reporting additional data in the first half of 2022 and to rapidly progressing our pipeline to realize the full potential of our gamma delta CAR T cell platform for patients,” commented Chen Schor, president and CEO of Adicet Bio.